Albumin-Bound Paclitaxel Where Will Your Data Go Next? Collecting data is time-consuming and expensive. Electronic transactions, including electronic medical records and the unification of many billing procedures, have transformed the rate at
Search Results
Where Your Data Is Going and Where It's Been
Jane M. Quigley
Undetectable Tumor Cell-Free DNA in a Patient With Metastatic Breast Cancer With Complete Response and Long-Term Remission
Natasha Hunter, Sarah Croessmann, Karen Cravero, Daniel Shinn, Paula J. Hurley, and Ben Ho Park
with estrogen receptor (ER)/progesterone receptor (PR)–negative, HER2-positive metastatic breast cancer who received trastuzumab and nab-paclitaxel in 2008 and experienced a complete remission (CR). Remarkably, she continues to have no evidence of
Systemic Treatment Strategies and Outcomes of Patients With Synchronous Peritoneal Metastases of Gastric Origin: A Nationwide Population-Based Study
Niels A.D. Guchelaar, Bo J. Noordman, Marion W. Welten, Myron T. van Santen, Micha J. de Neijs, Stijn L.W. Koolen, Rob H.A. Verhoeven, Esther Oomen-de Hoop, Pieter C. van der Sluis, Sjoerd M. Lagarde, Hanneke W.M. van Laarhoven, Ignace H.J.T. de Hingh, Geert-Jan Creemers, Bianca Mostert, Bas P.L. Wijnhoven, and Ron H.J. Mathijssen
, fluorouracil/leucovorin/oxaliplatin; RP, ramucirumab/paclitaxel; TPF, fluorouracil/cisplatin/docetaxel. Of the 222 patients receiving first-line therapy with complete follow-up, 99 (45%) underwent second-line systemic treatment ( Figure 2B , Supplementary
Strategies for the Management of Early-Stage Breast Cancer in Older Women
Lee S. Schwartzberg and Sarah L. Blair
: AC, anthracycline/cyclophosphamide; CMF, cyclophosphamide/methotrexate/fluorouracil; doc, docetaxel; G-CSF, granulocyte colony-stimulating factor; pts, patients; T, paclitaxel; TC, docetaxel/cyclophosphamide; TCH, docetaxel
First- and Second-Line Palliative Systemic Treatment Outcomes in a Real-World Metastatic Pancreatic Cancer Cohort
Esther N. Pijnappel, Willemieke P.M. Dijksterhuis, Lydia G. van der Geest, Judith de Vos-Geelen, Jan Willem B. de Groot, Marjolein Y.V. Homs, Geert-jan Creemers, Nadia Haj Mohammad, Marc G. Besselink, Hanneke W.M. van Laarhoven, Johanna W. Wilmink, and for the Dutch Pancreatic Cancer Group
that demonstrated a survival improvement compared with gemcitabine monotherapy was gemcitabine in combination with nab-paclitaxel, with a median OS of 8.5 months versus 6.7 months for gemcitabine alone. 5 , 14 Currently FOLFIRINOX and gemcitabine with
Counterpoint: Intraperitoneal Chemotherapy: An Investigational Treatment in Ovarian Cancer
Robert F. Ozols
Ozols RF . Intraperitoneal therapy in ovarian cancer: Time's up . J Clin Oncol 1991 ; 9 : 197 – 199 . 4 Markman M Bundy BN Alberts DS . Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high
A Novel Approach Using Sorafenib in Alpha Fetoprotein–Producing Hepatoid Adenocarcinoma of the Lung
Tatjana Gavrancic and Yeun-Hee Anna Park
/mL). The patient was diagnosed with stage IV HAL and started on palliative chemotherapy with carboplatin/paclitaxel and sorafenib (400 mg orally twice daily), followed by palliative radiation to the vertebrae for a total dose of 30 Gy. After 2 cycles of
Multidisciplinary Management of Pancreatic Cancer
Margaret A. Tempero
become more effective with the use of newer, presumably more active regimens, in particular FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, oxaliplatin) and gemcitabine plus nab-paclitaxel. Based on their benefit in the metastatic setting, these
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Lee-may Chen, Mihaela Cristea, Maria DeRosa, Eric L. Eisenhauer, David M. Gershenson, Heidi J. Gray, Rachel Grisham, Ardeshir Hakam, Angela Jain, Amer Karam, Gottfried E. Konecny, Charles A. Leath III, Joyce Liu, Haider Mahdi, Lainie Martin, Daniela Matei, Michael McHale, Karen McLean, David S. Miller, David M. O’Malley, Sanja Percac-Lima, Elena Ratner, Steven W. Remmenga, Roberto Vargas, Theresa L. Werner, Emese Zsiros, Jennifer L. Burns, and Anita M. Engh
tested these recommended regimens. 171 – 175 , 177 – 196 The most commonly-used regimen, paclitaxel 175/carboplatin, has been considered the standard postoperative chemotherapy for ovarian cancer for many years, so there are many studies in which it has
Integrating Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Practical Evidence-Based Considerations
Cesar A. Santa-Maria, Maureen O’Donnell, Raquel Nunes, Jean L. Wright, and Vered Stearns
weekly paclitaxel, and all patients received dose-dense (every 2 weeks) doxorubicin and cyclophosphamide (AC). A number of studies have been reported since then, with some, but not all, showing improvements in pCR in the ICI-containing arms ( Table 1 ). 3
